Whittier Trust Co. Sells 119,312 Shares of Johnson & Johnson (NYSE:JNJ)

Whittier Trust Co. trimmed its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 35.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 216,936 shares of the company's stock after selling 119,312 shares during the quarter. Whittier Trust Co.'s holdings in Johnson & Johnson were worth $31,373,000 as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. Swedbank AB lifted its position in shares of Johnson & Johnson by 5.3% during the 3rd quarter. Swedbank AB now owns 2,215,108 shares of the company's stock valued at $358,980,000 after acquiring an additional 111,570 shares during the last quarter. Principal Financial Group Inc. increased its position in Johnson & Johnson by 10.5% during the third quarter. Principal Financial Group Inc. now owns 3,472,312 shares of the company's stock worth $562,723,000 after buying an additional 329,473 shares during the last quarter. United Bank increased its position in Johnson & Johnson by 5.6% during the third quarter. United Bank now owns 3,788 shares of the company's stock worth $614,000 after buying an additional 202 shares during the last quarter. Second Half Financial Partners LLC acquired a new stake in shares of Johnson & Johnson in the third quarter valued at about $3,454,000. Finally, West Family Investments Inc. grew its position in shares of Johnson & Johnson by 13.2% in the third quarter. West Family Investments Inc. now owns 9,719 shares of the company's stock valued at $1,575,000 after purchasing an additional 1,134 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the stock. Morgan Stanley reduced their target price on shares of Johnson & Johnson from $175.00 to $163.00 and set an "equal weight" rating for the company in a research note on Thursday, January 23rd. Barclays raised their price target on shares of Johnson & Johnson from $159.00 to $166.00 and gave the stock an "equal weight" rating in a research note on Tuesday, January 28th. Guggenheim reiterated a "neutral" rating on shares of Johnson & Johnson in a research note on Monday, March 10th. Royal Bank of Canada reiterated an "outperform" rating and issued a $181.00 target price on shares of Johnson & Johnson in a research note on Wednesday, February 19th. Finally, Citigroup cut their target price on shares of Johnson & Johnson from $185.00 to $175.00 and set a "buy" rating for the company in a research note on Wednesday, December 11th. Nine investment analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $171.33.

Insider Activity

In other news, EVP Timothy Schmid sold 403 shares of the business's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the transaction, the executive vice president now owns 15,098 shares of the company's stock, valued at $2,357,552.70. The trade was a 2.60 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Robert J. Decker sold 6,999 shares of the business's stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the completion of the transaction, the vice president now directly owns 21,001 shares of the company's stock, valued at $3,483,645.88. This trade represents a 25.00 % decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Price Performance

Shares of Johnson & Johnson stock traded up $0.38 during midday trading on Friday, reaching $163.40. The company had a trading volume of 17,012,477 shares, compared to its average volume of 7,088,732. The stock has a fifty day simple moving average of $156.99 and a 200 day simple moving average of $156.17. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $169.99. The company has a market capitalization of $393.76 billion, a price-to-earnings ratio of 24.57, a price-to-earnings-growth ratio of 2.56 and a beta of 0.47.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping analysts' consensus estimates of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The firm had revenue of $22.52 billion during the quarter, compared to analyst estimates of $22.44 billion. During the same quarter in the previous year, the business earned $2.29 EPS. The business's quarterly revenue was up 5.3% compared to the same quarter last year. As a group, equities research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th were issued a $1.24 dividend. This represents a $4.96 annualized dividend and a dividend yield of 3.04%. The ex-dividend date of this dividend was Tuesday, February 18th. Johnson & Johnson's dividend payout ratio (DPR) is 74.59%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.